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1. Introduction 
In 1987, Chamot et al attempted to unify the various descriptions of osteoarticular disease 
associated with skin manifestations into a syndrome with the acronym SAPHO: synovitis, 
acne, pustulosis, hyperostosis, and osteitis (Chamot et al., 1987). Furthermore, the clinical 
feature of aseptic chronic recurrent multiple osteomyelitis (CRMO) accompanied by 
pustulosis with its typical presentation in the pediatric population  justifies the inclusion of 
CRMO into the same nosologic group as the SAPHO syndrome according to several authors 
(Juri et al., 1988,  Kahn et al., 1994). The differentiating clinical features of pediatric CRMO 
and adult hyperostosis with osteitis in patients with SAPHO syndrome seem to be mainly in 
localization of inflammation: in pediatric CRMO more often the extremities, in adults the 
axial skeleton preferentially with costosternoclavicular region (Rohekar et al., 2006). The 
wide spectrum of SAPHO syndrome describes overlapping clinical radiologic and 
pathologic characteristics that SAPHO shares with well-defined rheumatologic and 
dermatologic disorders, such as psoriatic arthritis (PsA) and ankylosing spondylitis (AS). 
Against this background the SAPHO syndrome has been often controversially discussed 
and more than 50 competing terms have been proposed for these or for very similiar 
entities, among others pustulotic arthro-osteitis and acquired hyperostosis syndrome (AHS) 
(Kirchhoff et al., 2003). With the increase in reports dealing with growing numbers of 
patients with SAPHO syndrome, this disease entity should be suspected in patients who 
fulfil one of the following diagnostic criteria (Assmann et al., 2011): (1) Osteoarticular 
manifestations with dermatosis like acne conglobata, acne fulminans, or palmoplantar 
pustulosis (PPP); (2) axial or appendicular osteitis and hyperostosis with or without 
dermatosis; (3) CRMO involving the axial or appendicular skeleton with or without 
dermatosis. However, in this broad spectrum of osteoarticular and chronic dermatological 
manifestations, osteitis seems to be the leading characteristic finding to determine the entity 
of SAPHO syndrome. 
2. Epidemiologic data 
The question of the frequency of the SAPHO syndrome is first of all an issue of history: In 
the 1960s, there were several reports of patients with musculoskeletal disorders and 
associated dermatologic lesions that were related to neutrophilic dermatitis (acne, PPP, 
pyoderma gangrenosum) (Windom et al., 1961). In 1972, a very rare pathological entity of 
unknown aetiology, CRMO, was first described – with or without PPP (Giedion et al., 1972; 
Bjorksten et al., 1978). Subsequently, several similar cases of pustulotic arthro-osteitis have 
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been reported and have been called by a variety of different terms such as Koehler`s disease, 
pyogenic sterile arthritis, or PAPA syndrome. However, only with the introduction of the 
acronym SAPHO as a unifying concept adequate data about the prevalence of this 
syndrome have been available: in the beginning of 1990, only 225 cases of SAPHO were 
described in Germany, Austria and Switzerland, and about 400 cases in France. 
Astonishingly enough, in 2009 there were estimates that the prevalence of SAPHO 
syndrome was probably no greater then 1 in 10,000 based on several reports about the 
disease from Japan and north-western Europe (Kahn et al., 1994a, 2009b). SAPHO can occur 
at any age, but demographic data show that it is a disease of children, young adults or 
middle-aged individuals, with a female predilection (Mueller-Richter et al., 2009). The 
disease has been reported mainly from Japan and Northern Europe, rarely from Anglo-
Saxon countries. It rarely occurs beyond the sixth decade of life (Van Doornum et al., 2000).   
However, it is difficult to determine whether this observation of geographic characteristics is 
related to immunogenic or ethnic differences or just to the failure to clinically recognize this 
syndrome in other areas than Japan or Europe. 
3. Etiology  
The aetiology of SAPHO syndrome is still not known but various theories have been 
postulated including genetic considerations, a possible link with an infectious agent and/or 
immune dysfunction.  
3.1 Genetics 
Several genetic abnormalities have been identified in patients with SAPHO syndrome. The 
association with the positivity for HLA B27 is only evident in cases with SAPHO syndrome 
and AS for the overall observation any association is not firmly established (Colina et al., 
2009; Earwaker et al., 2003, Kahn et al., 1994). A murine model developed for displaying the 
characteristic chronic multifocal aseptic osteomyelitis seen in SAPHO syndrome showed a 
mutation mapped to chromosome 18 affecting the proline-serine-threonine phosphatase 
interacting protein 2 (PSTPIP2). These results were confirmed by the localisation of the 
susceptibility gene from CRMO patients to chromosome 18q21.3-18q22 (Ferguson et al., 
2006; Golla et al., 2002). Similarly, pyogenic sterile arthritis, pyoderma gangrenosum, and 
acne syndrome (PAPA syndrome) has characteristics that may lend insight to the 
pathogenesis of SAPHO syndrome. PAPA has been found to be transmitted in an autosomal 
dominant fashion, and the predisposing genetic variation is located on chromosome 15 
affecting CD2-binding protein/PSTPIP1 (Yeon et al., 2000; Wise et al., 2002). The Majeed 
syndrome, an inherited disease first described in 1989, is characterized by neutrophilic 
dermatosis, multiple osteitic lesions, and abnormalities of erythropoesis (Majeed et al., 
1989). It is caused by a mutation on gene LPIN2, which encodes lipin 2. Lipin 2 may be 
involved in the apoptosis of polymorphonuclear neutrophiles (PMN) (Ferguson et al., 2005). 
Another pathway of putative importance is the NOD2/CARD15 system leading to an 
exaggerated response to intestinal bacteria through an up-regulation of the pro-
inflammatory transcription factor NFκB (Hayem et al., 2007). Recent studies have shown 
that p53 as an important negative regulator of NFκB can in turn be blocked by its own 
negative regulator, the E3 ubiquitin ligase human murine double minute Mdm2 (Gudkov et 
al., 2007). In this context, one of these studies reported susceptibility for SAPHO syndrome 
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due to the Mdm2 SNP T309G allele causing higher Mdm2 levels and thus a less efficient p53 
response with possibly higher NFκB activity (Assmann et al., 2010).  
3.2 Infectious agent 
Numerous investigations have brought forth the theory that osteitis and its dermatologic 
manifestations in patients with SAPHO syndrome are results of persisting pathogen of low 
virulence, or that the syndrome is triggered by a pathogen and sustained by an autoimmune 
response subsequent to that infectious challenge (Rohekar et al., 2006; Kahn et al., 1995). The 
infectious theory has long been proposed with conflicting reports, most of them implicating 
Propionibacterium acnes (P acnes), a slowly growing anaerobic microorganism usually found 
in acne lesions and considered to be a normal inhabitant of the skin (Kotilainen eta al., 1996). 
Furthermore, a part of coagulase negative staphylococcus aureus, haemophilus parainfluenzae, 
and actinomyces were reported to be associated with SAPHO syndrome (Rozin et al., 2007; 
Eyrich et al., 2000). However, positive cultures could not be found in all procedures of bone 
biopsy specimen. A possible explanation might be the ability of P. acnes to persist in bone 
lesions in a form that does not permit culturing. Although the bone lesions are often sterile, 
several recent studies have reported an association between SAPHO and P. acnes in 42% of 
the cases in total (Assmann et al., 2011). In particular, a recent study by Assmann et al. 
(2009) showed positive microbiological cultures for P. acnes in 67% of the bone biopsies. 
However, the mechanism that potentially leads to osteitis or arthritis by microbes is still 
unknown. The ex vivo effect of P. acnes on blood PMN isolated from patients with SAPHO 
syndrome was found to be dose dependant but impaired compared with rheumatoid 
arthritis (RA) or PsA patients. Interestingly, the PMN capacity for interleukin (IL-8) and 
tumor necrosis factor α (TNFα) production upon P. acnes stimulation was drastically lower 
in SAPHO patients, suggesting hyporeactivity to P. acnes, probably related to chronic 
exposure to this semi-pathogenic bacterium. In which way this potential desensitization to 
bacterial challenge plays a pathological role in the etiology of osteitis and/or dermatitis 
(acne, PPP) remains to be proved (Amital et al., 2008; Hurtado-Nedelec et al., 2008).  
3.3 Immune dysfunction 
According to this observation the SAPHO syndrome seems to be associated with 
inflammatory cytokine release and global neutrophil activation. In comparison with other 
rheumatologic disorders the SAPHO syndrome suggests a comparable hyperstimulation of 
innate immune response, as reflected by increased levels of IL-8 and TNFα by neutrophils in 
response to ex vivo stimulation (Magrey et al., 2009; Hurtado-Nedelec et al., 2008). 
Furthermore, elevated plasma levels of IL-8 and IL-18, but not IL-10 could be observed.  
Together with the above outlined hyporeactivity to P. acnes the scenario indicates an altered 
immune mechanism in patients with SAPHO syndrome. With regard to the characteristic 
lesion of the SAPHO syndrome, osteitis with hyperostosis and/or CRMO, respectively, 
bone biopsy showed hypercellular bone marrow with large numbers of plasma cells and 
neutrophile polymorphs in different samples (Gikas et al., 2009). However, a paucity of 
inflammation with predominant sclerosis and fibrosis frequently occurs in the chronic 
phase. Wagner et al. (2002) demonstrate an elevated level of TNFα expression in bone 
biopsy specimens. Generally, the bone lesions in SAPHO syndrome have to be described as 
a histologically nonspecific inflammation. Accordingly, osteitic lesions may preferentially 
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occur due to auto-amplified reaction to a low-virulence infection (Edlund et al., 1988). In this 
context, a comparison of T-cell stimulatory activity in skin lesions showed that P. acnes may 
trigger the non-specific activation of cell-mediated immunity, an immunological response 
that may be an attempt to eliminate the germ perpetuating the inflammation (Jappe et al., 
2004); a comparable investigation with bone specimens has not been conducted so far. In 
conclusion, the autoimmune inflammatory situation especially the one concerning the bone, 
bone marrow, and the skin cannot be classified into a predominately B-cell, plasma cell or T-
cell mediated disease.  
4. Clinical features 
The clinical features of SAPHO can approximately be summarized by its descriptive 
acronym: synovitis, acne, pustulosis, hyperostosis, and osteitis. 
4.1 Skin manifestations  
The tyical skin lesions seen in patients with SAPHO syndrome include PPP and acne (Kahn 
et al., 1994). Acne often manifests itself in its severe form with acne conglobata, acne 
fulminans or hidradenitis suppuratica. In addition, pyoderma gangrenosum, particularly in 
patients with concomitant Crohn`s disease, Sweet syndrome and other neutrophilic 
disorders are observed (Yamasaki et al., 2003). The association of SAPHO syndrome with 
different manifestations of psoriasis is typical, predominately the pustular psoriasis that 
shows the same histological pattern as the PPP (Hayem et al., 1999). Approximately two-
thirds of the patients with osteoarthritic lesions developed skin manifestions which could be 
defined as SAPHO syndrome. However, in some cases, the osteoarticular manifestations 
precede the skin features by years, making the clinical picture more suggestive of different 
rheumatologic disorders than of the SAPHO syndrome. In most cases, the time interval 
between the onset of skin and osteoarticular manifestations is less than two years, however, 
intervals of more than 20 years have been recorded as well (Sugimoto et al., 1998; Davies et 
al., 1999). 
 
Fig. 1. 53 year old female SAPHO patient: hand with pustulosis palmoplantaris 
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4.2 Osteoarticular manifestations 
The osteoarticular manifestations in patients with SAPHO syndrome implicate synovitis, 
hyperostosis and osteitis. Synovitis manifests in oligo- or polyarthritis; a monarthritis seems 
to be a rare clinical rheumatologic symptom. In terms of peripheral arthritis concerning the 
knees, hips and ankles synovitis is a frequent manifestation. Moreover, the axial arthritis is 
more common, reported in up to 91% of cases. In the same patients the clinically appearing 
arthritis of the mandibular joint is seen as well as a unilateral sacroileitis (Earwaker et al., 
2003). Colina et al. (2009) presented data of peripheral arthritis in patients preferentially 
younger than 25 years. 
However, the characteristic features of SAPHO syndrome are the aseptic osteitis and 
hyperostosis. The proof of the P. acnes in bone biopsies did not change the character of an 
inflammation missing typically histological signs of the bacterial septic osteomyelitis. 
Osteitis refers to inflammation of bone, which may involve the cortex and the medullary 
cavity. Clinically, the patient complains bone pain and tenderness. The anterior chest wall is 
a classic location of involvement in adult patients, in particular, the clavicles, sternum, and 
sterno-costo-clavicular (SCC) joints. The pattern of osteoarticular involvement seems to be 
age dependent and more frequently occurring in young and middle-aged adults (Hayem et 
al., 1999). The hyperostosis and osteitis often cause a tumor with hyperthermia of the skin in 
this region (Kahn et al., 1991). Although the SCC manifestation is typical, it is not exclusive  
 
Fig. 2. 23 year old female SAPHO patient: bilateral sternocostoclavicular osteitis and 
hyperostosis 
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nor pathognomonic (Kahn, 2002). The singular or multiple involvement of  the spine, pelvic 
girdle, sacroiliac joint, peripheral joint, long bones, and the mandibles is frequent, but not 
common (Mueller-Richter et al, 2009; Gikas et al., 2009). The clinical presentation of 
synovitis and osteitis in axial manifestation can not clearly distinguish between the two 
different entities. The CRMO, as manifestation of the SAPHO syndrome more common in 
children, appears often in the long bones, followed by clavicle and the spine. In those cases, 
the patients usually show localized swelling and pain accompanied by commonly 
generalized inflammation signs like fever and grippal symptoms. 
5. Radiological findings  
The predominant radiologic features of SAPHO syndrome include osteitis and hyperostosis 
with cortical thickening, periostitis, and cortical erosions in the concerned area. A variety of 
imaging tests are basically available for diagnosis and follow up SAPHO patients. 
Plain radiographs reveal nonspecific features suggestive of osteomyelitis in the regions of 
osteitis and hyperostosis. Imaging of osteitis and hyperostosis - typically located in the 
clavicle bone - reveals a characteristic poorly defined, moth-eaten, destructive lesion 
typically involving the medial and middle third of the bone, with expansion, sclerosis, and a 
solid or multi-laminated periosteal reaction. Flat bones, such as the ileum and mandible, 
also can be involved, displaying predominantly diffuse sclerosis. Peripheral arthritis is seen, 
but radiographic joint destruction as it occurs in RA is rare. However, early radiographic 
changes including juxtaarticular osteoporosis may be seen; as well as later changes such as 
joint space narrowing (Rohekar et al., 2006; Earwaker et al., 2003). With regard to osteitis 
and hyperostosis, the manifestation in the typical region of the SCC joint is commonly not 
clearly detectable by conventional radiographic imaging.  
Bone scintigraphy by technetium-99m phosphate is highly sensitive to detect the anterior 
chest wall lesions, and the characteristic “bull`s head” pattern of increased inflammatory 
activity. Furthermore, this tool of imaging is also suitable to detect occult and 
asymptomatic osteitis lesions in the skeletal system; the procedure is basically 
recommended to exclude multiple appearances of osteitis manifestations in the bones. 
Performing this investigation a highly detectable activity is commonly seen in the early 
phase of application of the technetium-99 isotope. However, the scintigraphy can not 
achieve a reliable differentiation between bacterial ostemyleitis, malignat tumor or 
osteitis/CRMO.  
X-ray computed tomography (CT) nicely demonstrates the osteoarticular lesions. The value 
of CT is that it demonstrates the location of the lesion and pattern of destruction in an area 
that may be poorly demonstrated radiographically as well as the nature of the periosteal 
response (Gikas et al., 2009). On CT, the mentioned pathological changes in osteitis lesions 
and hyperostosis appear as sharply defined hyperdense osteosclerosis of the periarticular 
bone, in some cases with lytic areas. CT can be clearly recommended as the primary 
diagnostic tool in cases of complications caused by osteitis and hyperostosis in the anterior 
chest wall, such as compression of the large vessels in the thoracic aperture; furthermore, 
the CT is basically employed for the imaging-guided bone biopsy of osteitis lesions if 
required.  
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The magnetic resonance imaging (MRI) is in wide use to identify the osteitis in its exact 
enlargement and inflammatory activity. MRI using fat-suppressed, T2-weighted, or short-t 
inversion recovery sequences reveals bone marrow edema as well as arthritis changes, and 
helps differentiate active from chronic less active lesions. MRI demonstrates bone 
expansion, marrow heterogeneity with bone, and adjacent soft tissue edema resulting in 
reduced T1-weighted signal intensity and increased T2-weighted modus. Furthermore, the 
MRI can be employed to identify the bone regions with the most pronounced inflammatory 
changes in order to carry out further diagnostic such as CT-guided bone biopsy (Kirchhoff 
et al., 2003). In addition, the MRI is supposed to be the most reliable diagnostic tool in the 
follow-up of osteitis activity under anti-inflammatory treatment.  
 
Fig. 3. 58 year old male SAPHO patient with osteitis of the right sterno-clavicular region and 
CT-guided biopsy of the sclerotic region (Kirchhoff et al, 2003) 
6. Laboratory diagnostic 
Patients with SAPHO syndrome often show symptoms of humoral inflammatory activity. C 
reactive protein (CRP) and erythrocyte sedimentation rate (ESR) are usually normal or 
slightly elevated during exacerbations. Abnormal levels are observed in only one third of 
the cases (Colina et al., 2009). Apart from reports of positive anti nuclear antibody (ANA) in 
30% of patients with CRMO (Janson et al., 2007) and anti-thyroid antibodies in 28% of 
patients with SAPHO, the data on autoimmunity in SAPHO is rather scant. A recent study 
investigated the prevalence of the autoantibody patterns classically associated with RA and 
PsA. Though their prevalence was increased compared to the general population, a specific 
antibody-profile could not be found (Grosjean et al., 2010). Extended investigations of 
numerous antibodies found that RA markers (rheumatoid factor (RF) and anti-cyclic 
citrulline peptides antibodies (anti-CCP2) were absent in SAPHO (Hurtado-Nedelec et al., 
2008). A pathway that might play a role in the bone damage observed in SAPHO syndrome 
is TNFα and RANKL-mediated osteoclast differentiation (Ritchlin et al., 2003). Jansson et al. 
recently reported elevated TNFα levels in two thirds of patients with CRMO. Furthermore, a 
different pattern of immunoglobulins with significantly higher levels of immunoglobulin A 
was observed compared to healthy controls. In conclusion the observed laboratory findings 
are somewhat contradictory. Nevertheless the co-occurrence of other immune-mediated 
conditions like psoriasis vulgaris, inflammatory bowel disease (IBD) and pyoderma 
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gangrenosum suggest a self-amplifying inflammatory response, possibly involving 
autoimmune mechanisms (Assmann et al., 2011). The possible role of infectious agents in 
SAPHO was already considered in the 1980’s when pathogens were isolated from different 
sites, namely anterior chest wall, spine, synovial fluid, bone tissue and skin pustules. A 
range of bacteria have been identified, including Staphylococcus aureus, Haemophilus 
parainfluenzae, Actinomyces, and even Treponema pallidum. However, it may be supposed that 
P. acnes play the major role, because they have been found more often than other 
microorganisms (Assmann et al., 2009). However, an extensive bacterial diagnostic 
procedure for detecting microbes like the P. acnes out of blood specimen, skin lesions, or 
bone-biopsy could not be recommended so far.  
7. SAPHO syndrome and psoriasis 
Regarding the definition of SAPHO syndrome as an arthro-osteo-cutaneus disease it is clear 
that SAPHO is an entity that fits into a variety of already established disease categories. 
There are aspects of SAPHO that are common in AS, in particular, the most frequently 
involvement of the axial skeleton. Furthermore, the radiologic findings often show 
sacroileitis which cannot be distinguished from typical AS in 13-52% cases (Earwaker eta al., 
2003). In addition, the skin osteoarticular manifestations could often lead to the diagnosis of 
PsA with axial skeleton manifestation and pustular psoriasis, a special subgroup of psoriatic 
disease. Furthermore, the PPP is histologically identical to that of the pustular psoriasis. 
However, the radiographic signs of osteitis with hyperostosis are not often seen in PsA 
(Rohekar et al., 2006). On the other hand, Kahn et al. (1994) have already demonstrated in a  
 
Fig. 4. Model of overlapping features in a spectrum of disease. (AS: ankylosing spondylitis; 
PsA: psoriatic arthritis; NSAIDs: nonsteroidal anti-inflammatory drugs; TNFα:  tumor 
necrosis factor α) (Rohekar et al., 2006) 
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multicenter study that the amount of psoriasis among the SAPHO patients is three times as 
much, compared with the general population. In some cases, psoriasis vulgaris has developed 
months or years after initial skin lesions with PPP together with osteoarthritic manifestations. 
With regard to clinical presentations of SAPHO patients figure four demonstrates a model for 
overlapping features in a spectrum of disease between AS and PsA. 
8. Strategy for management  
The knowledge of the clinical and the radiographic characteristics of SAPHO syndrome 
allows a relatively prompt and  correct diagnosis; however, the observation of the long-term 
follow-up of SAPHO patients demonstrates that patients have often been diagnosed first for 
other rheumatologic disorders such as RA, PsA, or AS – commonly with the additional 
remark “seronegative” and/or “atypical”.  The key to a correct diagnosis of SAPHO is the 
diagnosis of  osteitis and, in addition, in most of the cases, the observation of an interrelation 
or connection with cutaneous and osteoarticular manifestations. The diagnosis can be 
particularly difficult in patients with an isolated symptomatic bone lesion, when multiple 
differential diagnoses such as bacterial osteomyelitis, Langerhans cell histiocytosis, benign 
or malignant bone tumors (e.g. Ewing’s sarcoma), Paget’s disease, infectious arthritis or AS 
have to be taken into consideration. Further diagnostic problems may arise due to other 
incomplete manifestations of SAPHO. In addition to a careful physical examination, a total 
body skeleton scintigraphy is therefore strongly advised in patients with pain in the anterior 
chest wall and suspicion of SAPHO. Completing the reasonable diagnostic procedure 
includes laboratory tests with ESR and CRP, RA markers (rheumatoid factor (RF) and anti-
CCP2 antibodies); with regard to diagnostic imaging X-radiograph of the bone region 
concerned (clavicle, vertebral column, iliosacral joints, skeleton regions with peripheral 
arthritis) should be performed. In case of osteitis suspicious lesions further imaging with 
MRI in specific technical setting modalities is recommended. (see above).  
9. Treatment options  
Although the classification of SAPHO syndrome exists as a distinct disease entity, the 
overlap and similarities with other rheumatic diseases form the basis for trials investigating 
anti-rheumatic drugs that are the accepted standard for the treatment of PsA and other 
spondyloarthritides. Studies have been published with small numbers of patients treated 
with NSAIDs (Girschick et al., 1998), steroids (Benhamou et al., 1988; Schultz et al., 1999), 
and immunosuppressive agents that showed only partial efficacy. In detail, the SAPHO 
specific lesions like osteitis and/or CRMO often show therapeutic resistance against the 
established anti-rheumatic drugs including the disease modifying anti rheumatic drugs 
(DMARDs), whereas an accompanying arthritis and/or spondylarthritis seems to respond 
positively to the therapy. Investigations of methotrexate and azathioprine yielded no 
convincing results (Handrik et al., 1998; Kalke et al., 2001). However, several reports 
presenting promising results, obtained with bisphosphonates (Marshall et al., 2002; 
Kopterides et al., 2004; Just et al., 2008) or biologicals like TNFα-blockers (Olivieri et al., 
2002; Wagner et al., 2002 , Magrey 2009), have recently been published. In this context, it has 
been found that infliximab could show good therapeutic efficacy. Some cases, however, 
were reported with an amelioration of skin manifestations together with improvement of 
osteoarticular symptoms. With regard to a possible link to an infectious etiology of SAPHO 
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syndrome, several studies with small numbers of patients treated with antibiotics reported 
contradictory results (Schilling et al., 2000; Wagner et al., 1997). However, recently 
published data based on a prospective interventional study in 27 SAPHO patients show an 
effect of a four-month treatment with the antibiotic azithromycin (also with doxycycline and 
clindamycin in one patient each) with respect to MRI findings and to the activity of skin 
disease and osteitis (Figure 5). Three months after the end of antibiotic treatment, however, 
these effects had disappeared (Assmann et al., 2009). In rare cases SAPHO syndrome 
develops serious complications mostly based on vascular compression followed by blood 
stasis and venous thrombosis. In these cases a surgical intervention is often required. There 
are no data for the efficacy of radiation therapy available. 
 
Fig. 5. Activity scores and erythrocyte sedimentation rate (ESR) values (mean) of SAPHO 
patients treated with antibiotics. * differences of values between week 1 and week 16: 
p<0.05; ** differences of values between week 16 and week 28: p<0.05; HAS=health 
assessment score; MRI=magnet resonance imaging) (Assmann at al, 2009) 
10. Conclusions 
The SAPHO syndrome represents a constellation of overlapping osteoarticular and 
cutaneous manifestations. Its clinical presentation is heterogeneous and often incomplete, 
resulting in diagnostic difficulties. Although controversy still exists regarding its relation to 
the spondylarthropathies, SAPHO is now recognized as a distinct clinical entity. However, 
SAPHO continues to represent a nosologic enigma. Further examinations and a better 
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understanding of the underlying pathogenetic mechanisms are essential for the 
development of appropriate therapies.  Especially with regard to osteitis as the characteristic 
manifestation of the SAPHO syndrome, data concerning the existing treatment options are 
conflicting. The use of antibiotics has shown contradictory results in several reports 
although some patients are obviously responsive to this therapy. 
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